AI Summary
StalkThe stock remains in a healthy Stage 2 uptrend with persistent higher highs and rising EMAs beneath price. However, price is currently extended above the rising EMAs and showing overbought conditions (RSI and Options Score extreme), suggesting timing is unfavorable now. Execution should be deferred until a pullback into support zones—specifically the rising 9/20 EMAs around prior highs near $44–44.5—offers a more favorable entry. Medium-term bias stays bullish given the clear advancing regime, but risks of short-term exhaustion warrant patience.